Therapeutic anti-integrin (α4 and αL) monoclonal antibodies: Two-edged swords?

Immunology

Volumn 116, Issue 3, 2005, Pages 289-296

  González Amaro, Roberto ^a   Mittelbrunn, María ^b   Sánchez Madrid, Francisco ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Antibody responses; Genetics; Immunoglobulins; Xenotransplantation

Indexed keywords

ALPHA INTEGRIN; ALPHA4 INTEGRIN; EFALIZUMAB; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NATALIZUMAB; PROTEIN ALPHAL INTEGRIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANTIBODY RESPONSE; ANTIGEN FUNCTION; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG EFFECT; ENDOTHELIUM; ENTERITIS; EXTRAVASATION; HELPER CELL; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REVIEW; SYNAPTIC TRANSMISSION; TUBERCULOSIS; XENOTRANSPLANTATION;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; INTEGRIN ALPHA4BETA1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1;

EID: 27444447882     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02225.x     Document Type: Review

References (105)

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-87.
2. Hogg N, Laschinger M, Giles K, McDowall A. T-cell integrins: more than just sticking points. J Cell Sci 2003; 116:4695-705.
3. Sanchez-Madrid F, De Landazuri MO, Morago G, Cebrian M, Acevedo A, Bernabeu C. VLA-3: a novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization. Eur J Immunol 1986; 16:1343-9.
4. Hemler ME, Huang C, Schwarz L. The VLA protein family. Characterization of five distinct cell surface heterodimers each with a common 130,000 molecular weight beta subunit. J Biol Chem 1987; 262:3300-9.
5. Elices MJ, Osborn L, Takada Y, Grouse C, Luhowskyj S, Hemler ME, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60:577-84.
6. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 1989; 109:1321-30.
7. Cunningham SA, Rodriguez JM, Arrate MP, Tran TM, Brock TA. JAM2 interacts with alpha4beta1. Facilitation by JAM3. J Biol Chem 2002; 277:27589-92.
8. Altevogt P, Hubbe M, Ruppert M et al. The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. J Exp Med 1995; 182:345-55.
9. Newham P, Craig SE, Clark K, Mould AP, Humphries MJ. Analysis of ligand-induced and ligand-attenuated epitopes on the leukocyte integrin alpha4beta1: VCAM-1, mucosal addressin cell adhesion molecule-1, and fibronectin induce distinct conformational changes. J Immunol 1998; 160:4508-17.
10. Bridges LC, Tani PH, Hanson KR, Roberts CM, Judkins MB, Bowditch RD. The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1. J Biol Chem 2002; 277:3784-92.
11. Spring FA, Parsons SF, Ortlepp S, Olsson ML, Sessions R, Brady RL, Anstee DJ. Intercellular adhesion molecule-4 binds alpha (4) beta (1) and alpha (V) -family integrins through novel integrin-binding mechanisms. Blood 2001; 98:458-66.
12. Mould AP, Komoriya A, Yamada KM, Humphries MJ. The CS5 peptide is a second site in the IIICS region of fibronectin recognized by the integrin alpha 4 beta 1. Inhibition of alpha 4 beta 1 function by RGD peptide homologues. J Biol Chem 1991; 266:3579-85.
13. Kato R, Ishikawa T, Kamiya S et al. A new type of antimetastatic peptide derived from fibronectin. Clin Cancer Res 2002; 8:2455-62.
14. Puig-Kroger A, Sanz-Rodriguez F, Longo N, Sanchez-Mateos P, Botella L, Teixido J, Bernabeu C, Corbi AL. Maturation-dependent expression and function of the CD49d integrin on monocyte-derived human dendritic cells. J Immunol 2000; 165:4338-45.
15. Werr J, Xie X, Hedqvist P, Ruoslahti E, Lindbom L. Beta1 integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo. J Exp Med 1998; 187:2091-6.
16. van Oosten M, van de Bilt E, de Vries HE, van Berkel TJ, Kuiper J. Vascular adhesion molecule-1 and intercellular adhesion molecule-1 expression on rat liver cells after lipopolysaccharide administration in vivo. Hepatology 1995; 22:1538-46.
17. Marazuela M, Postigo AA, Acevedo A, Diaz-Gonzalez F, Sanchez-Madrid F, de Landazuri MO. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. Eur J Immunol 1994; 24:2483-90.
18. Walton LJ, Macey MG, Thornhill MH, Farthing PM. Intra-epithelial subpopulations of T lymphocytes and Langerhans cells in oral lichen planus. J Oral Pathol Med 1998; 27:116-23.
19. Koopman G, Parmentier HK, Schuurman HJ, Newman W, Meijer CJ, Pals ST. Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intercellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways. J Exp Med 1991; 173:1297-304.
20. Scheeren RA, Koopman G, Van der Baan S, Meijer CJ, Pals ST. Adhesion receptors involved in clustering of blood dendritic cells and T lymphocytes. Eur J Immunol 1991; 21:1101-5.
21. Kriegsmann J, Keyszer GM, Geiler T, Brauer R, Gay RE, Gay S. Expression of vascular cell adhesion molecule-1 mRNA and protein in rheumatoid synovium demonstrated by in situ hybridization and immunohistochemistry. Lab Invest 1995; 72:209-14.
22. Gonzalez-Amaro R, Sanchez-Madrid F. Cell adhesion molecules: selectins and integrins. Crit Rev Immunol 1999; 19:389-429.
23. Berlin C, Bargatze RF, Campbell JJ et al. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995; 80:413-22.
24. Acevedo A, del Pozo MA, Arroyo AG, Sanchez-Mateos P, Gonzalez-Amaro R, Sanchez-Madrid F. Distribution of ICAM-3-bearing cells in normal human tissues. Expression of a novel counter-receptor for LFA-1 in epidermal Langerhans cells. Am J Pathol 1993; 143:774-83.
25. Fraemohs L, Koenen RR, Ostermann G, Heinemann B, Weber C. The functional interaction of the beta 2 integrin lymphocyte function-associated antigen-1 with junctional adhesion molecule-A is mediated by the I domain. J Immunol 2004; 173:6259-64.
26. Hogg N, Henderson R, Leitinger B, McDowall A, Porter J, Stanley P. Mechanisms contributing to the activity of integrins on leukocytes. Immunol Rev 2002; 186:164-71.
27. Rosen GD, Sanes JR, LaChance R, Cunningham JM, Roman J, Dean DC. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell 1992; 69:1107-19.
28. Takada Y, Strominger JL, Hemler ME. The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis. Proc Natl Acad Sci USA 1987; 84:3239-43.
29. Nieto M, Gomez M, Sanchez-Mateos P et al. Expression of functionally active alpha 4 beta 1 integrin by thymic epithelial cells. Clin Exp Immunol 1996; 106:170-8.
30. Prosper F, Stroncek D, McCarthy JB, Verfaillie CM. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of alpha4 beta1 integrin expression and function. J Clin Invest 1998; 101:2456-67.
31. Miyake K, Weissman IL, Greenberger JS, Kincade PW. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 1991; 173:599-607.
32. Arroyo AG, Yang JT, Rayburn H, Hynes RO. Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity 1999; 11:555-66.
33. Arroyo AG, Yang JT, Rayburn H, Hynes RO. Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 1996; 85:997-1008.
34. Feuerbach D, Feyen JH. Expression of the cell-adhesion molecule VCAM-1 by stromal cells is necessary for osteoclastogenesis. FEBS Lett 1997; 402:21-4.
35. Spence S, Vetter C, Hagmann WK et al. Effects of VLA-4 antagonists in rat whole embryo culture. Teratology 2002; 65:26-37.
36. Mittelbrunn M, Molina A, Escribese MM et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci U S A 2004; 101:11058-63.
37. + T cell activation via the CS1 alternatively spliced domain of fibronectin. J Exp Med 1990; 172:1185-92.
38. Suzuki J, Isobe M, Izawa A, Takahashi W, Yamazaki S, Okubo Y, Amano J, Sekiguchi M. Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4. Transpl Immunol 1999; 7:65-72.
39. Coito AJ, Onodera K, Kato H, Busuttil RW, Kupiec-Weglinsk JW. Fibronectin-mononuclear cell interactions regulate type 1 helper T cell cytokine network in tolerant transplant recipients. Am J Pathol 2000; 157:1207-18.
40. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994; 95:94 (5):1722-8.
41. Ibbotson GC, Doig C, Kaur J, Gill V, Ostrovsky L, Fairhead T, Kubes P. Functional alpha4-integrin: a newly identified pathway of neutrophil recruitment in critically ill septic patients. Nat Med 2001; 7:465-70.
42. Hourihan H, Allen TD, Ager A. Lymphocyte migration across high endothelium is associated with increases in alpha 4 beta 1 integrin (VLA-4) affinity. J Cell Sci 1993; 104:1049-59.
43. Nandi A, Estess P, Siegelman M. Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity 2004; 20:455-65.
44. Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol 1995; 155:3856-65.
45. + T cell clones correlates with their levels of expression of adhesion molecules. J Exp Med 1992; 175:895-905.
46. Koopman G, Keehnen RM, Lindhout E, Newman W, Shimizu Y, van Seventer GA, de Groot C, Pals ST. Adhesion through the LFA-1 (CD11a/CD18) -ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994; 152:3760-7.
47. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267:891-3.
48. Montoya M, Sancho D, Vicente-Manzanares M, Sanchez-Madrid F. Cell adhesion and polarity during immune interactions. Immunol Rev 2002; 186:68-82.
49. Sims TN, Dustin ML. The immunological synapse: integrins take the stage. Immunol Rev 2002; 186:100-17.
50. Monks C, Freiberg B, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998; 395:82-6.
51. Hart DN, McKenzie JL. Isolation and characterization of human tonsil dendritic cells. J Exp Med 1988; 168:157-70.
52. Ardavin C, Shortman K. Cell surface marker analysis of mouse thymic dendritic cells. Eur J Immunol 1992; 22:859-62.
53. Smits HH, de Jong EC, Schuitemaker JH, Geijtenbeek TB, van Kooyk Y, Kapsenberg ML, Wierenga EA. Intercellular adhesion molecule-1/LFA-1 ligation favors human Th1 development. J Immunol 2002; 168:1710-6.
54. Chirathaworn C, Kohlmeier JE, Tibbetts SA, Rumsey LM, Chan MA, Benedict SH. Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J Immunol 2002; 168:5530-7.
55. Oppenheimer-Marks N, Davis LS, Bogue DT, Ramberg J, Lipsky PE. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol 1991; 147:2913-21.
56. + cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection. J Virol 2004; 78:3014-23.
57. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 2004; 173:3653-9.
58. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177:57-68.
59. Isobe M, Suzuki J, Yagita H, Okumura K, Yamazaki S, Nagai R, Yazaki Y, Sekiguchi M. Immunosuppression to cardiac allografts and soluble antigens by anti-vascular cellular adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies. J Immunol 1994; 153:5810-8.
60. Itoh S, Matsuzaki Y, Kimura T et al. Suppression of hepatic lesions in a murine graft-versus-host reaction by antibodies against adhesion molecules. J Hepatol 2000; 32:587-95.
61. Issekutz AC, Ayer L, Miyasaka M, Issekutz TB. Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease. Immunology 1996; 88:569-76.
62. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356:63-6.
63. Tsukamoto K, Yokono K, Amano K et al. Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. Cell Immunol 1995; 165:193-201.
64. Abraham WM, Ahmed A, Sielczak MW, Narita M, Arrhenius T, Elices MJ. Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. Am J Respir Crit Care Med 1997; 156:696-703.
65. Sagara H, Matsuda H, Wada N, Yagita H, Fukuda T, Okumura K, Makino S, Ra C. A monoclonal antibody against very late activation antigen-4 inhibits eosinophil accumulation and late asthmatic response in a guinea pig model of asthma. Int Arch Allergy Immunol 1997; 112:287-94.
66. Jackson DY, Quan C, Artis DR et al. Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents. J Med Chem 1997; 40:3359-68.
67. Chaudhuri A, Behan PO. Natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:1598-9.
68. Lew EA, Stoffel EM. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:1599.
69. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348:68-72.
70. Noseworthy JH, Kirkpatrick P. Natalizumab. Nat Rev Drug Discov 2005; 4:101-2.
71. Stacy KM. Therapeutic mAbs: saving lives and making billions. The Scientist 2005; 19:14.
72. Ma X, O'Brien ER. Antagonism of the alpha4 integrin subunit attenuates the acute inflammatory response to stent implantation yet is insufficient to prevent late intimal formation. J Leukoc Biol 2004; 75:1016-21.
73. Yang XD, Karin N, Tisch R, Steinman L, McDevitt HO. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking 1-selectin and very late antigen 4 adhesion receptors. Proc Natl Acad Sci USA 1993; 90:10494-8.
74. Kudlacz E, Whitney C, Andresen C et al. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists. J Pharmacol Exp Ther 2002; 301:747-52.
75. Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits. J Clin Invest 1988; 81:939-44.
76. Blazar BR, Carroll SF, Vallera DA. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin. Blood 1991; 78:3093-102.
77. Kakimoto K, Nakamura T, Ishii K, Takashi T, Iigou H, Yagita H, Okumura K, Onoue K. The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunol 1992; 142:326-37.
78. Nishikawa K, Guo YJ, Miyasaka M, Tamatani T, Collins AB, Sy MS, McCluskey RT, Andres G. Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J Exp Med 1993; 177:667-77.
79. Hasegawa Y, Yokono K, Taki T et al. Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol 1994; 6:831-8.
80. Fischer A, Friedrich W, Fasth A et al. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation report. Blood 1991; 77:249-56.
81. Le Mauff B, Hourmant M, Rougier JP et al. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991; 52:291-6.
82. Stoppa AM, Maraninchi D, Blaise D et al. Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease. Transpl Int 1991; 4:3-7.
83. Gauvreau GM, Becker AB, Boulet LP et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003; 112:331-8.
84. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-13.
85. Marecki S, Kirkpatrick P. Efalizumab. Nat Rev Drug Discov 2004; 3:473-4.
86. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002; 22:146-67.
87. Aruffo A, Hollenbaugh D. Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease. Curr Opin Immunol 2001; 13:683-6.
88. Greener M. MAbs turn. The Scientist 2005; 30:14.
89. Alter A, Duddy M, Hebert S et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170:170 (9):4497-505.
90. Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: the role of natalizumab. Expert Opin Biol Ther 2003; 3:995-1000.
91. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23:683-747.
92. Renno T, Krakowski M, Piccirillo C, Lin JY, Owens T. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J Immunol 1995; 154:944-53.
93. Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno R, Kuchroo VK, Miller SD. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2001; 107:995-1006.
94. Theien BE, Vanderlugt CL, Nickerson-Nutter C, Cornebise M, Scott DM, Perper SJ, Whalley ET, Miller SD. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 2003; 102:4464-71.
95. Ferguson TA, Stuart PM, Herndon JM, Griffith TS. Apoptosis, tolerance, and regulatory T cells - old wine, new wineskins. Immunol Rev 2003; 193:111-23.
96. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Group. B. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48:2085-91.
97. Cush JJ. Unusual toxicities with TNF inhibition, heart failure and drug-induced lupus. Clin Exp Rheumatol 2004; 22:5141-7.
98. + T cells is required for optimal antigen-dependent activation in vivo. J Immunol 2004; 173:4443-51.
99. Welsh CT, Rose JW, Hill KE, Townsend JJ. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha. J Neuroimmunol 1993; 43:161-7.
100. Isobe M, Suzuki J, Yamazaki S et al. Regulation by differential development of Th1 and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation 1997; 96:2247-53.
101. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138:591-600.
102. Gottlieb A, Krueger JG, Bright R et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42:428-35.
103. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45:665-74.
104. + T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse. Int Immunol 2004; 16:685-95.
105. + T helper cells. Eur J Immunol 2004; 34:1303-11.